DALI PHARMACEUTICALCO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.66 CNY | -5.03% |
|
-22.68% | -52.36% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 1,529 | 1,910 | 1,714 | 1,942 | 2,869 | 2,610 |
| Enterprise Value (EV) 1 | 1,202 | 1,602 | 1,430 | 1,685 | 2,641 | 2,413 |
| P/E ratio | 147 x | 141 x | 530 x | -46.5 x | -163 x | -132 x |
| Yield | 0.66% | - | 0.59% | - | - | - |
| Capitalization / Revenue | 3.81 x | 6.49 x | 8.02 x | 11.3 x | 21.7 x | 29.9 x |
| EV / Revenue | 2.99 x | 5.44 x | 6.69 x | 9.82 x | 20 x | 27.6 x |
| EV / EBITDA | 56.3 x | 71.5 x | 102 x | -61.6 x | -372 x | -318 x |
| EV / FCF | 15.5 x | -93.9 x | -85.4 x | 783 x | -60 x | -93.8 x |
| FCF Yield | 6.46% | -1.06% | -1.17% | 0.13% | -1.67% | -1.07% |
| Price to Book | 3.29 x | 4.08 x | 3.64 x | 4.7 x | 7.15 x | 7.19 x |
| Nbr of stocks (in thousands) | 219,700 | 219,700 | 219,700 | 219,700 | 219,700 | 219,700 |
| Reference price 2 | 6.959 | 8.692 | 7.800 | 8.840 | 13.06 | 11.88 |
| Announcement Date | 19-04-15 | 20-04-22 | 21-04-21 | 23-04-27 | 23-04-27 | 24-04-25 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 401.5 | 294.3 | 213.6 | 171.5 | 132.3 | 87.27 |
| EBITDA 1 | 21.34 | 22.39 | 14.03 | -27.35 | -7.108 | -7.585 |
| EBIT 1 | 3.298 | 6.173 | -1.728 | -42.62 | -22.58 | -24.13 |
| Operating Margin | 0.82% | 2.1% | -0.81% | -24.85% | -17.06% | -27.65% |
| Earnings before Tax (EBT) 1 | 12.62 | 17.12 | 3.776 | -41.59 | -17 | -17.37 |
| Net income 1 | 10.7 | 13.51 | 3.232 | -41.89 | -17.7 | -20.03 |
| Net margin | 2.67% | 4.59% | 1.51% | -24.43% | -13.38% | -22.95% |
| EPS 2 | 0.0473 | 0.0615 | 0.0147 | -0.1900 | -0.0800 | -0.0900 |
| Free Cash Flow 1 | 77.69 | -17.06 | -16.74 | 2.151 | -44.03 | -25.73 |
| FCF margin | 19.35% | -5.8% | -7.84% | 1.25% | -33.27% | -29.49% |
| FCF Conversion (EBITDA) | 364.08% | - | - | - | - | - |
| FCF Conversion (Net income) | 726% | - | - | - | - | - |
| Dividend per Share 2 | 0.0456 | - | 0.0460 | - | - | - |
| Announcement Date | 19-04-15 | 20-04-22 | 21-04-21 | 23-04-27 | 23-04-27 | 24-04-25 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 327 | 308 | 284 | 258 | 228 | 197 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 77.7 | -17.1 | -16.7 | 2.15 | -44 | -25.7 |
| ROE (net income / shareholders' equity) | 2.31% | 2.9% | 0.69% | -9.42% | -4.32% | -5.12% |
| ROA (Net income/ Total Assets) | 0.34% | 0.67% | -0.19% | -4.73% | -2.68% | -3.09% |
| Assets 1 | 3,134 | 2,023 | -1,706 | 886.5 | 660 | 649.2 |
| Book Value Per Share 2 | 2.110 | 2.130 | 2.140 | 1.880 | 1.830 | 1.650 |
| Cash Flow per Share 2 | 0.4600 | 0.3800 | 0.2900 | 0.8100 | 0.2000 | 0.0600 |
| Capex 1 | 3.61 | 21.9 | 23.8 | 24.2 | 29.5 | 7.7 |
| Capex / Sales | 0.9% | 7.43% | 11.15% | 14.11% | 22.27% | 8.82% |
| Announcement Date | 19-04-15 | 20-04-22 | 21-04-21 | 23-04-27 | 23-04-27 | 24-04-25 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -52.36% | 172M | |
| +19.62% | 43.27B | |
| +24.52% | 22.92B | |
| +20.29% | 15.43B | |
| +7.48% | 12.95B | |
| +42.51% | 11.83B | |
| -8.84% | 6.91B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +13.13% | 5.55B |
- Stock Market
- Equities
- 603963 Stock
- Financials Dali Pharmaceuticalco.,Ltd
